Wednesday, October 9, 2019

Alzheimer’s Disease Biological Causes

Alzheimers Disease Biological Causes Alzheimer’s disease is driven by two processes: extracellular deposits of beta amyloid and intracellular accumulation of tau protein.[9] â€Å"It is characterized by accumulation of amyloid-ÃŽ ² peptide, generated by proteolytic processing of the amyloid precursor protein (APP) by ÃŽ ²- and ÃŽ ³-secretase.†[10p554] The APP gene provides instructions for making APP. This protein is found in many tissues and organs including the brain and the spinal cord. It plays a role in cell growth, formation of new synapses, differentiation of neurons, cell adhesion, calcium metabolism, and protein trafficking.[10] The length of APP varies between 695 to 770 amino acids. Protein breakdown generates AÃŽ ², a 39- to 42-amino acid peptide. This form is the primary component of amyloid plaques found in the brains of AD.[10] APP may be processed via a non-amyloidogenic pathway that prevents AÃŽ ² formation or through a toxic, amyloidgenic pathway, resulting in AÃŽ ² plaque formation. In the non-amyloidogenic pathway, APP is processed in peripheral cells. In this pathway, APP is cleaved by an enzyme called ÃŽ ±-secretase followed by ÃŽ ³-secretase. These are integral membrane proteins where cleavage by ÃŽ ±-secretase occurs within the AÃŽ ² domain. Cleavage by ÃŽ ±-secretase prevents AÃŽ ² formation and releases the extracellular secreted APP ÃŽ ± fragment.[11] Research shows that secreted APP ÃŽ ± protects neurons, regulates stem cell production, plays a role in brain development, and promotes the formation of synapses and cell adhesion. The remaining C-terminal fragment of APP then undergoes either lysosome degradation or ÃŽ ³-secretase cleavage, which generates p3 and the APP intracellular domain.[11] In the amyloidogenic pathway, APP is primarily processed in neuronal cells. Within this pathway, APP is cleaved by ÃŽ ²-site APP cleaving enzyme 1 ( BACE1 ), followed by ÃŽ ³-secretase. BACE1 initiates the production of the toxic AÃŽ ² that plays a crucial role ea rly in the pathogenesis of AD.[11] Cleavage of APP by BACE1 releases the extracellular secreted APP ÃŽ ² fragment which is thought to assist with axon pruning and cell death.[12] BACE1 cuts APP to produce a membrane-bound C-terminal fragment C99 that is further processed by ÃŽ ³-secretase to generate AÃŽ ². The site of ÃŽ ³-secretase cleavage within the transmembrane domain of APP can vary and determines the type of AÃŽ ² that is produced, AÃŽ ² 39-42. Once produced, AÃŽ ² is usually secreted into the extracellular space via exocytosis.[12] AÃŽ ² is a major component of plaques that are found in both intracellular and extracellular locations. AÃŽ ² 42 is considered to be one of the main causes of these plaques because it clumps together more quickly than other isoforms, forming clusters and fibrils.[10] In individuals with AD, elevated concentrations of AÃŽ ² plaques can lead to many cellular dysfunctions. The presence of AÃŽ ² plaques alone is not enough to diagnose AD since ma ny people without cognitive decline have plaques. Tau is a protein in the microtubule-associated protein family. It has several physiological functions in healthy axons including microtubule assembly and stability, vesicle transport, neuronal outgrowth and neuronal polarity. This protein consists of 352 to 441 amino acids and presents in various isoforms in the brain.[10] In AD, tau protein is hyperphosphorylated, causing disruption in microtubule transport and loss of neuronal transmission. Tau phosphorylation is the addition of phosphate to a tau protein through regulation of tau kinases. In humans, the tau gene is positioned on chromosome 17. In a normal brain, there are two to three moles of phosphate per one mole of tau, indicating that this amount of phosphorylation is necessary for tau to perform its normal biological functions. When tau becomes hyperphosphorylated, the ratio of phosphate to tau increases three to four fold compared to normal phosphorylation levels. This incr eased amount of phosphate alters the function of tau, making it insoluble and lacking affinity for microtubules. This leads to the degradation of the microtubules and neuronal cell death.[10]

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.